Press/Media items
AIMS-2-TRIALS Newsletter
Press/Media: Public Engagement Activities › Professional
AIMS-2-TRIALS stands for Autism Innovative Medicine Studies-2-Trials. It began in June 2018 and will run until May 2023. The research programme includes a range of studies carried out by different groups. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for biological markers which indicate whether a person has or may develop particular characteristics. These markers could help to identify who may ultimately benefit from particular treatments. We will also test medicines to help with social difficulties, repetitive behaviours and sensory processing. To accelerate medicine development, we will build a network of connected people across Europe and beyond. AIMS-2-TRIALS will put Europe at the forefront of autism research.
References
AIMS-2-TRIALS Newsletter 2
AIMS-2-TRIALS Consortium
https://us19.campaign-archive.com/?u=4dff2edde4ed9e136ae6988e8&id=1bd23e3744
AIMS-2-TRIALS Newsletter 1
AIMS-2-TRIALS Consortium
https://us19.campaign-archive.com/?u=4dff2edde4ed9e136ae6988e8&id=ac8b4c1e23
Related Projects
AIMS-2-TRIALS: Autism Innovative Medicine Studies – 2 – Trials
Kas, M., Riemersma, I. & Østergaard, F.
01/06/2018 → 01/06/2023
Project: Research
ID: 86407714